JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M201571200 on March 13, 2002

J. Biol. Chem., Vol. 277, Issue 22, 19800-19805, May 31, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/22/19800    most recent
M201571200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mould, A. P.
Right arrow Articles by Humphries, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mould, A. P.
Right arrow Articles by Humphries, M. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Integrin Activation Involves a Conformational Change in the alpha 1 Helix of the beta  Subunit A-domain*

A. Paul MouldDagger, Janet A. Askari, Stephanie Barton, Adam D. Kline§, Paul A. McEwan, Susan E. Craig, and Martin J. Humphries

From the Wellcome Trust Centre for Cell-Matrix Research, School of Biological Sciences, University of Manchester, Manchester M13 9PT, United Kingdom

Received for publication, February 15, 2002, and in revised form, March 11, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The ligand-binding region of integrin beta  subunits contains a von Willebrand factor type A-domain: an alpha /beta "Rossmann" fold containing a metal ion-dependent adhesion site (MIDAS) on its top face. Although there is evidence to suggest that the beta A-domain undergoes changes in tertiary structure during receptor activation, the identity of the secondary structure elements that change position is unknown. The mAb 12G10 recognizes a unique cation-regulated epitope on the beta 1 A-domain, induction of which parallels the activation state of the integrin (i.e. competency for ligand recognition). The ability of Mn2+ and Mg2+ to stimulate 12G10 binding is abrogated by mutation of the MIDAS motif, demonstrating that the MIDAS is a Mn2+/Mg2+ binding site and that occupancy of this site induces conformational changes in the A-domain. The cation-regulated region of the 12G10 epitope maps to Arg154/Arg155 in the alpha 1 helix. Our results demonstrate that the alpha 1 helix undergoes conformational alterations during integrin activation and suggest that Mn2+ acts as a potent activator of beta 1 integrins because it can promote a shift in the position of this helix. The mechanism of beta  subunit A-domain activation appears to be distinct from that of the A-domains found in some integrin alpha  subunits.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Integrins are alpha /beta heterodimeric transmembrane receptors that have widespread essential functions in development, tissue organization, and the immune system (1). Integrins recognize a variety of extracellular matrix and cell-surface ligands; however, ligand recognition is frequently not constitutive but is instead under strict cellular control by "inside-out" signaling. Acquisition of the active state has also been shown to require divalent cations. For beta 1 integrins, ligand binding is promoted by Mg2+ or Mn2+ but only weakly by Ca2+ (2). A well known but unexplained property of Mn2+ is its ability to mimic the process of inside-out signaling to strongly up-regulate integrin function (3, 4).

The molecular basis of integrin-ligand interactions has been greatly elucidated by the recent x-ray crystal structure of alpha Vbeta 3 (5). The ligand binding "head" of the integrin is seen to contain a seven-bladed beta -propeller fold in the alpha  subunit and a von Willebrand factor type A-domain in the beta  subunit (beta A-domain).1 Cation-binding sites are present on the lower face of the beta -propeller domain and the upper face of the beta A-domain (5). The key regions involved in ligand recognition are loops on the upper surface of the beta -propeller and the upper face of the beta A-domain, which contains a metal ion-dependent adhesion site (MIDAS) (5-7). Nevertheless, as the crystal structure only provides a "snapshot" of one integrin conformation, attention is now focused on understanding the conformational changes that occur during the transition from the inactive to active state (8). These changes are thought to include shape shifting in the beta A-domain (4, 7).

The A-domain contains a central hydrophobic beta  sheet encircled by seven alpha  helices (alpha 1-alpha 7) (5). Some alpha  subunits also contain an A-domain and a key feature of the activation of these domains has been shown to be a large movement of the alpha 7 helix (9). Here we investigate conformational changes in the beta A-domain using the anti-beta 1 mAb 12G10, which recognizes a cation- and ligand-induced epitope (10, 11). We show that movements in the alpha 1 helix of the beta A-domain parallel changes in the activation state of the integrin. Our results provide insights into the mechanisms of Mn2+ and Ca2+-induced shape changes in the beta 1 subunit, and therefore into the opposing roles played by these divalent ions in regulating integrin function. Our findings also imply that the mechanism of beta A-domain activation is different to that of alpha A-domains.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Monoclonal Antibodies-- Rat mAbs 16 and 13 recognizing the human alpha 5 and beta 1 subunits, respectively, were gifts from Dr. K. Yamada (NIDCR, National Institutes of Health, Bethesda, MD). Mouse anti-human alpha 5 mAb P1D6 was a gift from Dr. E. Wayner (Fred Hutchinson Cancer Research Center, Seattle, WA). Mouse anti-human alpha 5 mAb SNAKA52 and mouse anti-human beta 1 mAb 12G10 were produced as described (10, 12). Mouse anti-human mAb TS2/16 was a gift from F. Sánchez-Madrid (Hospital de la Princesa, Madrid, Spain). Mouse anti-human mAbs 4B4 and P4C10 were purchased from Beckman Coulter (High Wycombe, UK) and Invitrogen (Paisley, Scotland, UK), respectively. All mAbs were used as purified IgG except P4C10 (as ascites).

Expression Vector Construction and Mutagenesis-- C-terminally truncated human alpha 5 and beta 1 constructs encoding alpha 5 residues 1-613 and beta 1 residues 1-455 fused to the hinge regions and CH2 and CH3 domains of human IgGgamma 1 were generated as previously described (13). To aid heterodimerization, the CH3 domain of the alpha 5 construct contained a "hole" mutation, whereas the CH3 domain of the beta 1 construct carried a "knob" mutation as described (13, 14). Mutations in the A-domain of the beta 1 subunit were carried out using oligonucleotide-directed PCR mutagenesis, as described (13). Oligonucleotides were purchased from MWG Biotech (Milton Keynes, UK). The presence of the mutations was verified by DNA sequencing.

Transfection-- Chinese hamster ovary cells L761h variant (13) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine, and 1% nonessential amino acids (growth medium). Cells were detached using 0.05% (w/v) trypsin, 0.02% (w/v) EDTA in PBS, and plated overnight into six-well culture plates (Costar). 1 µg of wild-type or mutant beta 1-(1-455)-Fc, and 1 µg of alpha 5-(1-613)-Fc DNA/well was used to transfect the cells using LipofectAMINE Plus reagent (Invitrogen) according to the manufacturer's instructions. After 4 days, medium was harvested by centrifugation at 1000 × g for 5 min.

For comparison of wild-type tralpha 5beta 1-Fc with tralpha 5beta 1-Fc containing the D130A or R154R/AS mutations in beta 1, 75-cm2 flasks of subconfluent CHOL761h cells were transfected with 5 µg of wild-type or mutant beta 1-(1-455)-Fc and 5 µg of alpha 5-(1-613)-Fc DNA as described above. After 4 days, culture supernatants were harvested by centrifugation at 1000 × g for 5 min. Wild-type or mutant heterodimers were purified using Protein A-Sepharose essentially as described previously (13).

Proteins-- A recombinant fragment of fibronectin containing type III repeats 6-10 (III6-10) was produced and purified as previously described (15). III6-10 and mAb 12G10 were biotinylated as before (11, 15), except that sulfo-LC-NHS biotin (Perbio, Chester, UK) was used in place of sulfo-NHS biotin.

Effect of Divalent Cations on 12G10 Binding-- Purified integrin was diluted to approximately 1 µg/ml in Dulbecco's PBS and added to the wells of a half-area enzyme immunoassay/radio immunoassay plate (Costar, Corning Science Products, High Wycombe, UK; 25 µl/well) for 16 h at room temperature. Wells were blocked for 1-3 h with 200 µl of 5% (w/v) BSA, 150 mM NaCl, 0.05% (w/v) NaN3, 25 mM Tris-Cl, pH 7.4 (blocking buffer). Wells were then washed three times with 200 µl of 150 mM NaCl, 25 mM Tris-Cl, pH 7.4, containing 1 mg/ml BSA (buffer A). Buffer A was treated with Chelex beads (Bio-Rad, Hemel Hempstead, UK) to remove any small contaminating amounts of endogenous Ca2+ and Mg2+ ions. 12G10 (0.1 µg/ml) in buffer A with varying concentrations of Mn2+, Mg2+, or Ca2+ was added to the plate (50 µl/well). The plate was then incubated at 30 °C for 2 h. Unbound antibody was aspirated, and the wells washed three times with buffer A. Bound antibody was quantitated by addition of 1:500 dilution of ExtrAvidin® peroxidase conjugate (Sigma, Poole, UK) in buffer A for 20 min at room temperature (50 µl/well). Wells were then washed four times with buffer A, and color was developed using 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) substrate (50 µl/well). Background binding to BSA was subtracted from all measurements. Measurements obtained were the mean ± S.D. of four replicate wells.

For comparison of the effects of divalent cations on 12G10 binding to wild-type tralpha 5beta 1-Fc and the R154R/AS mutant, the assay was performed using 12G10 concentrations that gave approximately half-maximal antibody binding in 1 mM Mn2+ (0.1 µg/ml for wild-type tralpha 5beta 1-Fc, 10 µg/ml for R154R/AS mutant). Binding was measured in 2 mM EDTA, Mn2+, Mg2+, or Ca2+. Measurements obtained were the mean ± S.D. of four replicate wells.

Effect of Divalent Cations on III6-10 Binding-- Measurement of the binding of III6-10 to purified wild-type or mutant tralpha 5beta 1-Fc was performed exactly as described for biotinylated 12G10 (see above), except that biotinylated III6-10 was incubated with integrin for 3 h at 30 °C. All assays were performed using a concentration of biotinylated III6-10 that gave approximately half-maximal ligand binding in 1 mM Mn2+ (0.1 µg/ml).

Sandwich ELISA for Epitope Expression-- A 96-well plate (Costar half-area enzyme immunoassay/radio immunoassay) was coated with goat anti-human gamma 1 Fc (Jackson Immunochemicals, Stratech Scientific, Luton, UK) at a concentration of 2.6 µg/ml in Dulbecco's PBS (50 µl/well) for 16 h. The coating solution was replaced with blocking buffer for 1 h. The blocking solution was removed, and cell culture supernatants were added (25 µl/well) for 1 h. All supernatants were assayed in triplicate, and supernatant from mock-transfected cells was used as a negative control. The plate was washed three times in buffer A containing 1 mM MnCl2 (buffer B; 200 µl/well), and anti-alpha 5 or anti-beta 1 mAbs (10 µg/ml, or 1 µg/ml for SNAKA52) were added (50 µl/well). The plate was incubated for 2 h and then washed three times in buffer B. Peroxidase-conjugated anti-rat or anti-mouse secondary antibodies (1:1000 dilution in buffer B; Jackson Immunochemicals) were added (50 µl/well) for 30 min, the plate washed four times in buffer B, and color was developed using 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) substrate (50 µl/well). All steps were performed at room temperature.

Each experiment shown is representative of at least three separate experiments.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Induction of the 12G10 Epitope on the beta 1 A-domain Correlates with Competency for Ligand Binding-- To investigate the mechanisms of integrin activation, we employed a recently described system for expression of recombinant soluble alpha 5beta 1 (13). For these particular studies, we have used a truncated version of alpha 5beta 1, alpha 5-(1-613)beta 1-(1-455), fused to the Fc region of human IgGgamma 1 (hereafter referred to as tralpha 5beta 1-Fc). This heterodimer contains the ligand-binding head and thigh domains of the integrin (5) and has been shown to retain the properties of the full-length receptor (13). In contrast to previous mutagenesis-based analyses of integrin function, which have largely employed cell-expressed integrins, this system is ideal (a) because it permits the rapid analysis of the effects of mutations and (b) because the effects of mutations that normally preclude expression at the plasma membrane can be studied. 12G10 is a previously characterized activating mAb directed against the beta 1 A-domain, whose binding to alpha 5beta 1 is modulated by divalent cations and ligand (10, 11). The binding of 12G10 to tralpha 5beta 1-Fc was promoted by Mn2+ and to a lesser degree by Mg2+, whereas Ca2+ was inhibitory (Fig. 1A). The effects of these cations on 12G10 binding closely paralleled their effects on ligand binding (Fig. 1B). Importantly, as for the native integrin, ligand binding is strongly activated by Mn2+ and more weakly by Mg2+, whereas Ca2+ is a very poor activator (16). These results show that the beta A-domain undergoes conformational changes in response to cation binding (reported by modulation of the 12G10 epitope) that correspond with changes in the activation state of the integrin.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of divalent cations on the binding of mAb 12G10 (A) and III6-10 fragment of fibronectin (B) to tralpha 5beta 1-Fc. Binding of 12G10 or III6-10 was measured in the presence of varying concentrations of Mn2+ (), Mg2+ (black-square), or Ca2+ (black-triangle). For tests of specificity, the binding of biotinylated 12G10 to tralpha 5beta 1-Fc could be inhibited >95% by a hundredfold excess of unlabelled 12G10; III6-10 binding to tralpha 5beta 1-Fc could be inhibited >90% by the anti-alpha 5 mAb 16 (data not shown).

Mutation of the MIDAS Site in the beta A-domain Leads to Loss of Induction of 12G10 Binding by Mn2+/Mg2+-- The identity of the cation-binding site(s) involved in activation of beta 1 integrins by Mn2+ and Mg2+ is unknown. The MIDAS is a strong candidate for this site, but this has been difficult to test experimentally because mutation of the MIDAS residues completely abrogates ligand recognition (although expression is unaffected; Refs. 17-19). In agreement with these previous studies, tralpha 5beta 1-Fc with MIDAS mutations did not bind ligand under any cation conditions, even though such mutants (e.g. D130A) retained all the epitopes of conformation-sensitive alpha 5 and beta 1 mAbs (Table I). Because mAb binding was retained, we tested the effect of the D130A mutation on the ability of divalent cations to regulate 12G10 binding to tralpha 5beta 1-Fc (Fig. 2). The binding of 12G10 to the D130A mutant in the absence of divalent cations was similar to the wild-type integrin (comparing Fig. 1A with Fig. 2); however, the ability of Mn2+ and Mg2+ to stimulate 12G10 binding was totally lost in the MIDAS mutant. Interestingly, the inhibition of 12G10 binding by Ca2+ seen for the wild-type integrin was enhanced in the MIDAS mutant. Similar results were obtained with a "double" MIDAS mutation D130A/S132A (data not shown). Conversely, mutation of cation-binding sites in the alpha 5 subunit beta -propeller did not affect the capacity of Mn2+ or Mg2+ to modulate 12G10 binding (20). Hence, these data demonstrate that the MIDAS is a Mn2+/Mg2+-binding site and that occupancy of this site induces conformational movements that are detected by changes in 12G10 binding.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Summary of mAb reactivity with beta 1 A-domain mutants
CHO L761h cells were transfected with alpha 5-(1-613)-Fc and wild-type or mutant beta 1-(1-455)-Fc. Cell culture supernatants were analyzed for reactivity with anti-alpha 5 and anti-beta 1 mAbs by sandwich ELISA. The anti-alpha 5 mAbs recognize the beta -propeller domain (12), and the anti-beta 1 mAbs are all directed against the beta A-domain (11, 21). +++, reactivity 70-100% of wild-type integrin; ++, reactivity 50-70% of wild-type integrin; +, reactivity 20-50% of wild-type integrin; +/-, reactivity < 20% of wild-type integrin. None of the mutations (except D130A) affected recognition of the III6-10 fragment of fibronectin (data not shown).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of MIDAS mutation D130A on cation-modulated binding of 12G10 to tralpha 5beta 1-Fc. Binding of 12G10 was measured in the presence of varying concentrations of Mn2+ (), Mg2+ (black-square), or Ca2+ (black-triangle). The assay was performed in parallel with that shown in Fig. 1A.

The Cation-responsive Portion of the 12G10 Epitope Maps to Arg154/Arg155 in the alpha 1 Helix of the beta A-domain-- The epitopes of all function-altering mAbs that map to the beta 1 A-domain include one or more residues in the sequence Asn207-Lys218 (21), which based on homology to beta 3 is predicted to form the alpha 2 helix (5, 22). The epitope of 12G10 also maps to this region and includes Lys218 as part of its epitope (11); however, among these regulatory mAbs, 12G10 has the unique property of showing strong cation modulation of binding (11). Therefore, part of the 12G10 epitope may be distinct from that of the other beta A-domain mAbs. While investigating the mechanism of integrin activation using alanine-scanning mutagenesis,2 we found two mutations that selectively perturbed 12G10 binding (Table I). Mutation of Arg154 or Arg155 to Ala reduced 12G10 binding by ~65 and ~35%, respectively, whereas mutation of surrounding residues (Asn151, Met153, Ile156) had no effect. A double mutation R154R/AS reduced 12G10 binding by >80% but did not perturb the binding of other function-modulating mAbs against the beta 1 A-domain (Table I), and also had no effect on the apparent affinity of ligand binding (data not shown). Therefore, Arg154 and Arg155 appear to form part of the 12G10 epitope.3 By homology to the structure of the beta 3 A-domain (5), Arg154/Arg155 lie at the base of the alpha 1 helix and these residues would be predicted to be in sufficiently close proximity to Lys218 in the alpha 2 helix for all three residues to contribute to the 12G10 epitope (23).

The above data suggest that Arg154 and Arg155 form part of the 12G10 epitope, but these residues do not contribute to other A-domain epitopes. Hence, do Arg154/Arg155 form the cation-regulated region of the 12G10 epitope? To test this proposal, we compared the effects of divalent cations on 12G10 binding to the R154R/AS mutant and wild-type tralpha 5beta 1-Fc. The results (Fig. 3A) showed that the abilities of Mn2+, Mg2+, and Ca2+ to modulate 12G10 binding were strongly attenuated by the R154R/AS mutation. The mutation did not affect the cation regulation of ligand binding (Fig. 3B) or of alpha 5 epitopes (Ref. 11; data not shown), suggesting that the mutation does not itself affect cation-induced conformational changes but rather that the ability of 12G10 to detect these changes is specifically compromised by the mutation. Therefore, the portion of the 12G10 epitope that is responsive to cation binding lies in the alpha 1 helix, indicating that the position of this helix is different in the active and inactive states.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of R154R/AS mutation on cation-modulated binding of 12G10 (A) and fibronectin fragment III6-10 (B) to tralpha 5beta 1-Fc. Binding of 12G10 or III6-10 to wild-type tralpha 5beta 1-Fc or tralpha 5beta 1-Fc with the mutation R154R/AS in beta 1 was measured in the presence of 2 mM EDTA (white bars), 2 mM Mn2+ (black bars), 2 mM Mg2+ (gray bars), or 2 mM Ca2+ (hatched bars). In A, 12G10 was used at concentration of 0.1 µg/ml for wild-type tralpha 5beta 1-Fc or 10 µg/ml for the R154R/AS mutant (conditions that gave approximately half-maximal 12G10 binding in the presence of 2 mM Mn2+). The control mutation M153A had no effect on the cation modulation of 12G10 binding (data not shown).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Using the anti-beta 1 mAb 12G10 as a probe of beta A-domain conformation, we have shown that: (i) the beta A-domain undergoes shape changes that correlate with changes in the activation state of the integrin, (ii) occupancy of the MIDAS site in the beta A-domain by Mn2+ or Mg2+ induces these changes, and (iii) beta A-domain activation involves movement of the alpha 1 helix. Taking these results together, we propose that the beta A-domain can exist in at least two conformational states: an "active" conformation with the alpha 1 helix in a position characterized by high 12G10 binding and an "inactive" conformation with the alpha 1 helix in a different position, characterized by low 12G10 binding.

Movement of the alpha 1 helix appears to form an essential part of the activation mechanism of the beta A-domain because alpha 1 movement closely parallels the activation state and a lack of alpha 1 movement (in the Ca2+-occupied integrin) corresponds to low activity. Furthermore, the epitopes of function-blocking anti-chicken beta 1 mAbs have been shown to include residues in the alpha 1 helix (24), and the epitopes of function-altering anti-human beta 1 mAbs include residues in the alpha 2 helix, which lies adjacent to alpha 1 (5, 21). Based on previous analyses of the mode of action of regulatory anti-integrin mAbs (2, 25), it appears that they are likely to function allosterically by stabilizing the position of alpha 1 in either the active or inactive conformation. Additionally, it has been shown that mutation of residues in the alpha 1 helix can activate ligand binding (26).

Our data provide evidence that the MIDAS is primarily a Mn2+/Mg2+ binding site and suggest an explanation for the opposing effects of Mn2+ and Ca2+ on beta 1 integrin function. Mn2+ can induce a large shift in the equilibrium between active and inactive states because of its ability to promote alpha 1 helix movement upon binding to the MIDAS site. On the other hand, Ca2+ is unable to cause the same conformational change. It is likely that Ca2+ can occupy the MIDAS site because Ca2+ can support low affinity ligand binding to alpha 5beta 1 and high affinity binding of activation-independent ligands to alpha 4beta 1 (34). However, Ca2+ binding to sites other than the MIDAS appears to shift the equilibrium toward the inactive conformation (low 12G10 binding), as shown by the strong inhibition of 12G10 binding by Ca2+ in the D130A mutant.

Some integrins contain an A-domain in their alpha  subunits (e.g. the beta 2 family). These domains can exist in inactive ("closed") or active ("open") states dependent upon movement of the C-terminal helix (alpha 7). The open form can be induced in the presence of a ligand or pseudo-ligand, or by locking the position of alpha 7 (9, 27-29). There appear to be some differences between the activation mechanism of alpha A-domains and the beta A-domain. First, the nature of the metal ion at the MIDAS does not directly influence the equilibrium between inactive and active states in alpha A-domains (4, 28), whereas, based on data reported here for the beta A-domain, the nature of the divalent ion can markedly affect this equilibrium. Second, in contrast to the beta A-domain, there is no evidence for allosteric regulation of activity by mAbs to alpha A-domains whose epitopes include residues in the alpha 1 helix (30). Third, although in alpha A-domains the open form can be induced by mutation of residues that form a hydrophobic pocket surrounding alpha 7 (31), mutation of the equivalent residues in beta 1 does not alter integrin activity.2 Fourth, the crystal structure of the beta 3 A-domain indicates that the alpha 7 helix is unlikely to undergo large conformational movements (5). All these findings suggest that the beta A-domain is regulated differently to the alpha A-domains in that movement of the alpha 1 helix (rather than alpha 7) is a key feature of beta A-domain activation. Nevertheless, comparison of the open and closed forms of alpha A-domains shows that there is an inward shift of the alpha 1 helix in the open form (9), and a similar movement could take place in the beta A-domain (Fig. 4).


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of conformational changes in alpha  and beta  subunit A-domains. A model of the beta 1 A-domain was built using an alignment against the beta 3 A-domain crystal structure (5) in the program LOOK (version 3.5, Molecular Applications Group, Palo Alto, CA; Ref. 42). Modeling was carried out using an automated segment matching algorithm, followed by restrained energy minimization refinement under SEGMOND (43, 44). Representations of A-domains were produced using SETOR (45), using the Protein Data Bank entry 1JLM for the closed form of the alpha M A-domain. beta  strands are shown in blue, alpha  helices are shown in red, and cysteine bridges are in yellow. The divalent ion at the MIDAS site is depicted by a green sphere. In the model of the beta 1 A-domain the positions of the alpha 1, alpha 2, and alpha 7 helices are indicated by thin arrows, and the side chains of Arg154 and Arg155 are shown as green sticks. The metal ion at the ADMIDAS site of the beta A-domain (5) is omitted for the sake of clarity. The two A-domains are viewed from approximately the same orientation. In the transition from the closed (inactive) to the open (active) form of the alpha M A-domain, there is a large downward shift of the alpha 7 helix and a small inward movement of the alpha 1 helix (thick arrows). In the transition from the inactive to active form of the beta 1 A-domain, the alpha 1 helix changes position, whereas the alpha 7 helix may not move. The alpha 2 helix region contains the epitopes of activating and inhibitory anti-beta 1 mAbs (21).

In integrins that contain an A-domain in the alpha  subunit, the beta A-domain does not participate directly in ligand binding (4). Nevertheless, Mn2+ and mAbs to the beta A-domain can strongly modulate the activity these integrins (3, 4). The epitopes of activating and inhibitory anti-beta 2 mAbs have also been shown to contain residues in the alpha 1 helix of the beta 2 A-domain (4, 32, 33). Therefore, movement of the alpha 1 helix may also regulate the activation state of this class of integrin.

Is alpha 1 helix movement involved in the activation of integrins by inside-out signaling? It has been shown that the expression of the 12G10 epitope correlates with the activity of cell-surface beta 1 integrins, whereas expression of other beta 1 A-domain epitopes is constitutive (35, 36). Because 12G10 differs from the other A-domain mAbs in having part of its epitope in the alpha 1 helix, these data imply that inside-out signaling alters the position of alpha 1. Inside-out signaling may also cause a shift in the conformation of the alpha 1 helix in beta 2 integrins. For alpha Lbeta 2 and alpha Mbeta 2, activating cytoplasmic domain mutations led to the induction of the mAb 24 epitope, which includes Arg122 in the alpha 1 helix of the beta 2 A-domain (4, 37). It has often been questioned whether Mn2+-induced integrin activation accurately mimics physiologic activation. However, a common feature of both types of activation appears to be movement of the alpha 1 helix; hence, their molecular mechanisms may be very similar.

Finally, how might alpha 1 helix movement be important for activation? The top (MIDAS) face of the beta A-domain interacts closely with the upper surface of the alpha  subunit beta -propeller domain (5). In particular, loops on the top face of the A-domain close to the alpha 1 helix (notably the alpha 2-alpha 3 loop) contact loops on the beta -propeller domain that participate in ligand recognition. Hence, alpha 1 helix movement is likely to affect the alpha  subunit/beta subunit interface, potentially leading to changes in exposure of the ligand binding loops. In support of this hypothesis, we have shown that divalent cations affect the binding of inhibitory mAbs on the alpha  subunit (11); the epitopes of these mAbs include residues in the same loops that are important for ligand recognition (12, 38, 39). In integrins with an A-domain in the alpha  subunit, there is evidence that the MIDAS face of the beta A-domain is in contact with the lower face of the alpha A-domain (40); hence, conformational changes in the beta A-domain could affect the position of the alpha 7 helix in the alpha A-domain and thereby alter the activation state of this domain.

In summary, we have shown that a conformational shift in the alpha 1 helix of the beta A-domain is involved the regulation of integrin activity. Integrins are important therapeutic targets in many inflammatory and vascular disorders (41), and our findings suggest a novel way in which highly specific regulators of integrin activity could be developed. A more complete understanding of the activation mechanism will require crystallization of an integrin in both active and inactive states.

    ACKNOWLEDGEMENTS

We thank A. Coe, P. Stephens, and M. Robinson for the alpha 5 and beta 1 constructs. We are grateful to K. Yamada, E. Wayner, and F. Sánchez-Madrid for mAbs, K. Yamada and S. Aota for the III6-10 construct, A. Arnaout for the coordinates of the alpha vbeta 3 structure, and J. Bella for advice on molecular modeling.

    Note Added in Proof

After this manuscript was accepted for publication, the crystal structure of integrin alpha vbeta 3 in complex with an RGD ligand was reported (Xiong, K.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S., and Arnaout, M. A. (2002) Science 296, 151-155). The pivotal conformational change between the unliganded (5) and liganded structures is an inward movement of the alpha 1 helix in the beta A-domain. This conformational change appears to be causally linked to occupancy of the MIDAS site by a Mn2+ ion in the liganded structure.

    FOOTNOTES

* This work was supported in part by grants from the Wellcome Trust (to M. J. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Wellcome Trust Centre for Cell-Matrix Research, School of Biological Sciences, University of Manchester, 2.205 Stopford Bldg., Oxford Rd., Manchester M13 9PT, United Kingdom. Tel.: 44-161-275-5649; Fax: 44-161-275-5082; E-mail: paul.mould@man.ac.uk.

§ Supported by a Wellcome Prize studentship. Present address: Eisai London Research Laboratories Ltd., University College London, London WC1E 6BT, United Kingdom.

Supported by a studentship from the Biotechnology and Biological Sciences Research Council.

Published, JBC Papers in Press, March 13, 2002, DOI 10.1074/jbc.M201571200

2 A. P. Mould, J. A. Askari, S. Barton, and M. J. Humphries, manuscript in preparation.

3 In further support of this proposal, 12G10 reacts only weakly with a chimeric beta 1 containing Asn207-Lys218 of human beta 1 in a backbone of chicken beta 1 (CH mutant; Ref. 21), in contrast to the other function-modulating mAbs, which show good reactivity. In chicken beta 1 Arg154 and Arg155 are both altered to Glu and Lys, respectively, whereas other residues in this region are unchanged (W. Puzon-McLaughlin, Y. Takada, A. P. Mould, and M. J. Humphries, unpublished observations).

    ABBREVIATIONS

The abbreviations used are: beta A-domain, beta subunit von Willebrand factor A-domain; alpha A-domain, alpha subunit von Willebrand factor A-domain; MIDAS, metal ion-dependent adhesion site; mAb, monoclonal antibody; PBS, phosphate-buffered saline; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; tralpha 5beta 1-Fc, recombinant soluble integrin heterodimer containing C-terminally truncated alpha 5 and beta 1 subunits (alpha 5 residues 1-613 and beta 1 residues 1-455) fused to the Fc region of human IgGgamma 1; CHO, Chinese hamster ovary.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sheppard, D. (2000) Matrix Biol. 19, 203-209[CrossRef][Medline] [Order article via Infotrieve]
2. Mould, A. P. (1996) J. Cell Sci. 109, 2613-2618[Medline] [Order article via Infotrieve]
3. Dransfield, I., Cabanas, C., Craig, A., and Hogg, N. (1992) J. Cell Biol. 116, 219-226[Abstract/Free Full Text]
4. Lu, C., Shimoka, M., Zang, Q., Takagi, J., and Springer, T. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 2393-2398[Abstract/Free Full Text]
5. Xiong, J.-P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S., and Arnaout, M. A. (2001) Science 294, 339-345[Abstract/Free Full Text]
6. Lee, O.-J., Rieu, P., Arnaout, M. A., and Liddington, R. (1995) Cell 80, 631-638[CrossRef][Medline] [Order article via Infotrieve]
7. Humphries, M. J. (2000) Biochem. Soc. Trans. 28, 311-339[Medline] [Order article via Infotrieve]
8. Humphries, M. J., and Mould, A. P. (2001) Science 294, 316-317[Free Full Text]
9. Lee, O.-J., Bankston, L. A., Arnaout, M. A., and Liddington, R. (1995) Structure 3, 1333-1340[Medline] [Order article via Infotrieve]
10. Mould, A. P., Garratt, A. N., Askari, J. A., Akiyama, S. K., and Humphries, M. J. (1995) FEBS Lett. 363, 118-122[CrossRef][Medline] [Order article via Infotrieve]
11. Mould, A. P., Garratt, A. N., Puzon-McLaughlin, W., Takada, Y., and Humphries, M. J. (1998) Biochem. J. 331, 821-828
12. Burrows, L., Clark, K., Mould, A. P., and Humphries, M. J. (1999) Biochem. J. 344, 527-533
13. Coe, A. P. F., Askari, J. A., Kline, A. D., Robinson, M. K., Kirby, H., Stephens, P. E., and Humphries, M. J. (2001) J. Biol. Chem. 276, 35854-35866[Abstract/Free Full Text]
14. Ridgway, J. B., Presta, L. G., and Carter, P. (1996) Protein Eng. 9, 617-621[Abstract/Free Full Text]
15. Mould, A. P., Askari, J. A., Aota, S., Yamada, K. M., Irie, A., Takada, Y., Mardon, H. J., and Humphries, M. J. (1997) J. Biol. Chem. 272, 17283-17292[Abstract/Free Full Text]
16. Mould, A. P., Akiyama, S. K., and Humphries, M. J. (1995) J. Biol. Chem. 270, 26270-26277[Abstract/Free Full Text]
17. Takada, Y., Ylanne, J., Mandelman, D., Puzon, W., and Ginsberg, M. H. (1992) J. Cell Biol. 119, 913-921[Abstract/Free Full Text]
18. Kamata, T., Puzon, W., and Takada, Y. (1995) Biochem. J. 305, 945-954
19. Puzon-McLaughlin, W., and Takada, Y. (1996) J. Biol. Chem. 271, 20438-20443[Abstract/Free Full Text]
20. Kline, A. D. (2001) Analysis of Integrin Activation and Divalent Cation Binding by Site-directed Mutagenesis.Ph.D. thesis , University of Manchester, Manchester, United Kingdom
21. Takada, Y., and Puzon, W. (1993) J. Biol. Chem. 268, 17597-17601[Abstract/Free Full Text]
22. Tuckwell, D. S., and Humphries, M. J. (1997) FEBS Lett. 400, 297-303[CrossRef][Medline] [Order article via Infotrieve]
23. Davies, D. R., and Cohen, G. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7-12[Abstract/Free Full Text]
24. Shi, D. T., Boetigger, D., and Buck, C. A. (1997) J. Cell Sci. 110, 2619-2628[Abstract]
25. Mould, A. P., Akiyama, S. K., and Humphries, M. J. (1996) J. Biol. Chem. 271, 20365-20374[Abstract/Free Full Text]
26. Bajt, M. L., Loftus, J. C., Gawaz, M. P., and Ginsberg, M. H. (1992) J. Biol. Chem. 267, 22211-22216[Abstract/Free Full Text]
27. Emsley, J., Knight, G. C., Farndale, R., Barnes, M. J., and Liddington, R. C. (2000) Cell 100, 47-56
28. Xiong, J.-P., Li, R., Essafi, M., Stehle, T., and Arnaout, M. A. (2000) J. Biol. Chem. 275, 38762-38767[Abstract/Free Full Text]
29. Shimoaka, M., Lu C., Palframan, R. T., von Andrian, U. H., McCormack, A., Takagi, J., and Springer, T. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6009-6014[Abstract/Free Full Text]
30. Oxvig, C., Lu, C., and Springer, T. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2215-2220[Abstract/Free Full Text]
31. Huth, J. R., Olejniczak, E. T., Mendoza, R., Liang, H., Harris, E. A. S., Lupher, M. L., Jr., Wilson, A. E., Fesik, S. W., and Staunton, D. E. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5231-5236[Abstract/Free Full Text]
32. Huang, C., Zang, Q., Takagi, J., and Springer, T. A. (2000) J. Biol. Chem. 275, 21514-21524[Abstract/Free Full Text]
33. Xiong, Y.-M., and Zhang, L. (2001) J. Biol. Chem. 276, 19340-19349[Abstract/Free Full Text]
34. Chen, L. L., Whitty, A., Scott, D., Lee, W. C., Cornebise, M., Adams, S. P., Petter, R. C., Lobb, R. R., and Pepinsky, R. B. (2001) J. Biol. Chem. 276, 36520-36529[Abstract/Free Full Text]
35. Belkin, A. M, Retta, S. F., Pletjushkina, O. Y., Balzac, F., Silengo, L., Fassler, R., Koteliansky, V. E., Burridge, K., and Tarone, G. (1997) J. Cell Biol. 139, 1583-1595[Abstract/Free Full Text]
36. Mastrangelo, A. M., Homan, S. M., Humphries, M. J., and LaFlamme, S. (1998) J. Cell Sci. 112, 217-229[Abstract]
37. Lu, C., Takagi, J., and Springer, T. A. (2001) J. Biol. Chem. 276, 14642-14648[Abstract/Free Full Text]
38. Mould, A. P., Askari, J. A., and Humphries, M. J. (2000) J. Biol. Chem. 275, 20324-20336[Abstract/Free Full Text]
39. Humphries, J. D., Askari, J. A., Zhang, X.-P., Takada, Y., Humphries, M. J., and Mould, A. P. (2000) J. Biol. Chem. 275, 20337-20345[Abstract/Free Full Text]
40. Zang, Q., Lu, C., Huang, C., Takagi, J., and Springer, T. A. (2001) J. Biol. Chem. 275, 22202-22212[Abstract/Free Full Text]
41. Curley, G. P., Blum, H., and Humphries, M. J. (1999) Cell. Mol. Life Sci. 56, 427-441[CrossRef][Medline] [Order article via Infotrieve]
42. Lee, C., and Irizarry, K. (2001) IBM Systems J. 40, 592-603
43. Levitt, M. (1992) J. Mol. Biol. 266, 507-533
44. Levitt, M. (1983) J. Mol. Biol. 170, 723-764[Medline] [Order article via Infotrieve]
45. Evans, S. V. (1993) J. Mol. Graphics 11, 134-138[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
D. Valdramidou, M. J. Humphries, and A. P. Mould
Distinct Roles of {beta}1 Metal Ion-dependent Adhesion Site (MIDAS), Adjacent to MIDAS (ADMIDAS), and Ligand-associated Metal-binding Site (LIMBS) Cation-binding Sites in Ligand Recognition by Integrin {alpha}2{beta}1
J. Biol. Chem., November 21, 2008; 283(47): 32704 - 32714.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
D. Vial and P. J. McKeown-Longo
PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the {alpha}v{beta}5 and {alpha}5{beta}1 integrins
J. Cell Sci., May 15, 2008; 121(10): 1661 - 1670.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Tchesnokova, P. Aprikian, O. Yakovenko, C. LaRock, B. Kidd, V. Vogel, W. Thomas, and E. Sokurenko
Integrin-like Allosteric Properties of the Catch Bond-forming FimH Adhesin of Escherichia coli
J. Biol. Chem., March 21, 2008; 283(12): 7823 - 7833.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
M. Parsons, A. J. Messent, J. D. Humphries, N. O. Deakin, and M. J. Humphries
Quantification of integrin receptor agonism by fluorescence lifetime imaging
J. Cell Sci., February 1, 2008; 121(3): 265 - 271.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
E. Puklin-Faucher, M. Gao, K. Schulten, and V. Vogel
How the headpiece hinge angle is opened: new insights into the dynamics of integrin activation
J. Cell Biol., October 23, 2006; 175(2): 349 - 360.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Chen, W. Yang, M. Kim, C. V. Carman, and T. A. Springer
Regulation of outside-in signaling and affinity by the beta2 I domain of integrin {alpha}Lbeta2
PNAS, August 29, 2006; 103(35): 13062 - 13067.